Evidence map›Paper›PMID 27471645›Full record

ArticleOncoimmunology2016

CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses.

Phillip D Fromm, Michael S Papadimitrious, Jennifer L Hsu, Nicolas Van Kooten Losio, Nirupama D Verma, Tsun Ho Lo, Pablo A Silveira, Christian E Bryant, Cameron J Turtle, Rebecca L Prue and 12 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 3 countries.

Phillip D FrommANZAC Research Institute, Concord, NSW, Australia; Sydney Medical School, University of Sydney, Camperdown, NSW, Australia.
Michael S PapadimitriousANZAC Research Institute, Concord, NSW, Australia; Sydney Medical School, University of Sydney, Camperdown, NSW, Australia.
Jennifer L HsuANZAC Research Institute , Concord, NSW, Australia.
Nicolas Van Kooten LosioANZAC Research Institute, Concord, NSW, Australia; Sydney Medical School, University of Sydney, Camperdown, NSW, Australia.
Nirupama D VermaANZAC Research Institute, Concord, NSW, Australia; Sydney Medical School, University of Sydney, Camperdown, NSW, Australia.
Tsun Ho LoANZAC Research Institute, Concord, NSW, Australia; Sydney Medical School, University of Sydney, Camperdown, NSW, Australia.
Pablo A SilveiraANZAC Research Institute, Concord, NSW, Australia; Sydney Medical School, University of Sydney, Camperdown, NSW, Australia.
Christian E BryantANZAC Research Institute, Concord, NSW, Australia; Sydney Medical School, University of Sydney, Camperdown, NSW, Australia.
Cameron J TurtleProgram in Immunology, Fred Hutchinson Cancer Research Center , Seattle, WA, USA.
Rebecca L PrueMater Medical Research Institute , Raymond Terrace, QLD, Australia.
Peter VukovicMater Medical Research Institute , Raymond Terrace, QLD, Australia.
David J MunsterMater Medical Research Institute , Raymond Terrace, QLD, Australia.
Tomoko NagasakiMater Medical Research Institute , Raymond Terrace, QLD, Australia.
Ross T BarnardSchool of Chemistry and Molecular Biosciences, University of Queensland , St Lucia, QLD, Australia.
Stephen M MahlerANZAC Research Institute , Concord, NSW, Australia.
Sébastien A AnguilleAustralian Institute for Bioengineering and Nanotechnology, University of Queensland , St Lucia, QLD, Australia.
Zwi BernemanAustralian Institute for Bioengineering and Nanotechnology, University of Queensland , St Lucia, QLD, Australia.
Lisa G HorvathAntwerp University Hospital, Center for Cell Therapy and Regenerative Medicine, Antwerp, Belgium; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia; The Kinghorn Cancer Center/Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
Kenneth F BradstockANZAC Research Institute, Concord, NSW, Australia; Sydney Medical School, University of Sydney, Camperdown, NSW, Australia; Chris O'Brien Lifehouse, Department of Medical Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Douglas E JoshuaSydney Medical School, University of Sydney, Camperdown, NSW, Australia; Haematology Department, Westmead Hospital, Westmead, NSW, Australia.
Georgina J ClarkANZAC Research Institute, Concord, NSW, Australia; Sydney Medical School, University of Sydney, Camperdown, NSW, Australia.
Derek N J HartANZAC Research Institute, Concord, NSW, Australia; Sydney Medical School, University of Sydney, Camperdown, NSW, Australia; Department of Haematology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia; Department of Haematology, Concord Repatriation General Hospital, Concord, NSW, Australia.
Anzac Research Institute · AUThe University of Sydney · AUMater Research · AUThe University of Queensland · AUFred Hutch Cancer Center · USRoyal Prince Alfred Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are numerous transcriptional, proteomic and functional differences between monocyte-derived dendritic cells (Mo-DC) and primary blood dendritic cells (BDC). The CMRF-56 monoclonal antibody (mAb) recognizes a cell surface marker, which is upregulated on BDC following overnight culture. Given its unique ability to select a heterogeneous population of BDC, we engineered a human chimeric (h)CMRF-56 IgG4 mAb to isolate primary BDC for potential therapeutic vaccination. The ability to select multiple primary BDC subsets from patients and load them with in vitro transcribed (IVT) mRNA encoding tumor antigen might circumvent the issues limiting the efficacy of Mo-DC. After optimizing and validating the purification of hCMRF-56(+) BDC, we showed that transfection of hCMRF-56(+) BDC with mRNA resulted in efficient mRNA translation and antigen presentation by myeloid BDC subsets, while preserving superior DC functions compared to Mo-DC. Immune selected and transfected hCMRF-56(+) BDC migrated very efficiently in vitro and as effectively as cytokine matured Mo-DC in vivo. Compared to Mo-DC, hCMRF-56(+) BDC transfected with influenza matrix protein M1 displayed superior MHC peptide presentation and generated potent antigen specific CD8(+) T-cell recall responses, while Wilms tumor 1 (WT1) transfected CMRF-56(+) BDC generated effective primary autologous cytotoxic T-cell responses. The ability of the combined DC subsets within hCMRF-56(+) BDC to present mRNA delivered tumor antigens merits phase I evaluation as a reproducible generic platform for the next generation of active DC immune therapies.

Indexed as

Antigen presentationCTLimmunoselectionmRNA transfectiontherapeutic DC vaccination

Identifiers

PMID27471645
PMCPMC4938320
OpenAlexW2412318937

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.